id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-2426-0006,FDA,FDA-2025-E-2426,Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPA,Notice,Determinations,2026-02-13T05:00:00Z,2026,2,2026-02-13T05:00:00Z,2026-08-13T03:59:59Z,2026-02-13T20:03:13Z,2026-02901,1,0,09000064b91aa6fb
FDA-2025-E-2426-0005,FDA,FDA-2025-E-2426,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-11-24T05:00:00Z,2025,11,2025-11-24T05:00:00Z,,2025-11-25T02:49:57Z,,0,0,09000064b909407e
FDA-2025-E-2426-0004,FDA,FDA-2025-E-2426,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-09-22T04:00:00Z,2025,9,2025-09-22T04:00:00Z,,2025-09-22T23:26:39Z,,0,0,09000064b8fd20ee
FDA-2025-E-2426-0003,FDA,FDA-2025-E-2426,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-08-19T04:00:00Z,2025,8,2025-08-19T04:00:00Z,,2025-08-20T00:18:38Z,,0,0,09000064b8f07e2c
FDA-2025-E-2426-0001,FDA,FDA-2025-E-2426,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-07-16T04:00:00Z,2025,7,2025-07-16T04:00:00Z,,2025-07-16T22:17:10Z,,0,0,09000064b8e7b6d6
FDA-2025-E-2426-0002,FDA,FDA-2025-E-2426,Patent Extension Application from GlaxoSmithKline (on behalf of Glaxo Group Limited),Other,Application,2025-07-16T04:00:00Z,2025,7,2025-07-16T04:00:00Z,,2025-07-16T22:17:18Z,,0,0,09000064b8e7b6d8